University of Dundee

#AstraZeneca #Drug discovery #Europe #European Federation of Pharmaceutical Industries and Associations #FDA #Francis Crick Institute #Hypertension #Lung cancer #Mental health #Tropical disease #University of Dundee #Wellcome Trust

DDW Highlights: 26 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a report showed patients in Europe face barriers to medicine access. Elsewhere,… Read More

#Podcasts

#Drug discovery #Tropical disease #University of Dundee

University of Dundee leads effort to tackle ‘cruel’ disease 

The University of Dundee has revealed plans to develop therapies to tackle a deadly tropical disease.  The £10 million ($13.4 million) project will accelerate research on new therapies for schistosomiasis. The disease is a chronic illness caused by microscopic worms found in contaminated freshwater. Found largely in Africa, South America, and Asia,… Read More

#News

#Colorectal cancer #Funding #Oncology #Start-ups #University of Arizona #University of Dundee

Start-up receives $4m towards ‘one-shot’ cancer drug

A drug discovery company co-founded by researchers at the University of Dundee and the University of Arizona has received $4 million in venture funding.  Branch Therapeutics, founded in November 2024, is a preclinical stage company seeking to develop drugs that are orally bioavailable, well-tolerated, and can treat multiple cancer types. … Read More

#Business & Investment #Cancer Research #News #Start-up Zone

Protein degradation
#Boehringer Ingelheim #Collaboration #PROTAC #Protein degradation #University of Dundee

Collaboration award for Dundee PROTAC drug discovery project

A research team at the University of Dundee have been recognised for their work with industry partner, Boehringer Ingelheim, with the Biochemical Society’s 2026 Industry and Academic Collaboration Award.  The award ‘recognises and promotes an outstanding individual or team who has made an inspirational contribution to the… Read More

#News

Degeneration of dopaminergic neuron in Parkinson's disease
#Collaboration #Parkinson's #SandboxAQ #The Michael J Fox Foundation for Parkinson’s Research (MJFF) #University of Dundee

Partners launch $25m initiative to develop Parkinson’s treatments

SandboxAQ is collaborating with the University of Dundee in the UK to improve its inhibitor for the gene most commonly associated with Parkinson's disease (PD). The company has signed a $25 million research grant through The Michael J Fox Foundation for Parkinson's Research (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE) programme. Read More

#Business & Investment #News

Biologic drugs
#Asthma #Biologics #Eczema #Glen Clova Scientific #Start-ups #University of Dundee

Improving the standard of biological drugs

DDW Editor Reece Armstrong speaks to Dr Steven Powell, co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Spun-out of the Univeristy of Dundee in… Read More

#Exclusive Content #Start-up Zone

Scotland
#AstraZeneca #Kidney disease #NHS Scotland #Partnership #Scotland #University of Dundee #University of Glasgow

Scottish partnership to boost kidney disease research

A new partnership between NHS Scotland, AstraZeneca and the Universities of Dundee and Glasgow hopes to accelerate research into treating chronic kidney disease. The partners will work together on new medicines to slow the progression of chronic kidney disease, reducing the risk that patients might need… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

Seed fund
#Biologics #Seed funding #Start-ups #University of Dundee

Dundee spin-out raises £4m to advance VLPs

Glen Clova Scientific has closed a £4 million (approximately $5 million) seed financing round, led by Norcliffe Capital together with investment from DSW Ventures, TRICAPITAL Angels and Scottish Enterprise. Glen Clova Scientific was founded in 2022 as a spin out from the University of Dundee to… Read More

#News #Start-up Zone

Esther Sammler
#Biogen #Clinical trial #Denali Therapeutics #Neurodegenerative disorders #Parkinson's #University of Dundee

New trial will investigate LRRK2 inhibitors for Parkinson’s

A study that could lead to the development of new treatments for Parkinson’s disease has launched at the University of Dundee, Scotland. The study is utilising LRRK2 inhibitors developed by Denali Therapeutics and Biogen. Mutations in the LRRK2 protein kinase are the most frequent cause of… Read More

#Editor's Choice #News